

SUPPLEMENTAL TABLES

Table S1 Psychoactive Medication Exposures

CNS Active Medication Class	Ever Exposed	%	Prescribed at Intake	%
AED/Mood Stabilizer*	102	32.28	69	21.84
Alpha Agonist*	65	20.57	43	13.61
Anticholinergic/Dopamine Agonist	6	1.90	5	1.58
Atypical Antidepressant*	16	5.06	9	2.85
Atypical Antipsychotic*	77	24.37	52	16.46
Barbiturate	11	3.48	1	0.32
Benzodiazepine*	61	19.30	47	14.87
Beta Blocker	5	1.58	5	1.58
First Generation Antihistamine	13	4.11	8	2.53
First Generation Antipsychotic*	15	4.75	9	2.85
Lithium	5	1.58	1	0.32
Melatonin	47	14.87	41	12.97
Muscle Relaxer/Nerve Pain	3	0.95	1	0.32
NET Inhibitor	12	3.80	6	1.90
NMDA Antagonist	4	1.27	1	0.32
Non-Benzodiazepine Anxiolytic	2	0.63	1	0.32
Nootropic	1	0.32	1	0.32
Opioid*	1	0.32	1	0.32
Opioid Antagonist	2	0.63	2	0.63
Sedative/Hypnotic*	2	0.63	1	0.32
SNRI	4	1.27	2	0.63
SSRI*	71	22.47	46	14.56
Stimulant*	57	18.04	23	7.28
TCA	3	0.95	2	0.63
Triptan	1	0.32	1	0.32

Summary of patient exposures to each of the 25 CNS active medication classes. “Ever” refers to any time prior to date of intake.

*Refers to classes where patients had tried or were taking multiple medications within the same class (i.e., cases of intraclass polypharmacy).

Table S2 Referrals to Specialized Neurodevelopmental Services from CARING

	N	%
Core Medical Specialties		
Outside Psychiatry	10	3.16
Outside Neurology	8	2.53
UCLA Autism Evaluation Clinic	8	2.53
Outside Genetics	6	1.90
Developmental-Behavioral Pediatrics	4	1.27
Specialty Psychiatric and Psychological Services		
Social Skills Therapy Based Programs	30	9.49
Psychiatric Day Programs	21	6.65
Outside Clinical Psychology and Psychotherapy	16	5.06
Family Therapy, Resources, and Support	6	1.90
Educational and Resource Consultants	4	1.27
Cognitive and Neuropsychological Testing	2	0.63
thinkSMART (executive function training)	2	0.63
Electroconvulsive Therapy	1	0.32
Feeding Therapy	1	0.32
Condition Specific Clinics and Support Groups		
Condition Specific Clinics at Outside Institutions	2	0.63
UCLA 22q11.2 Deletion Clinic	2	0.63
Dup15q Alliance	1	0.32
UCLA Cerebral Palsy Clinic	1	0.32
UCLA Child OCD, Anxiety, and Tic Disorders Clinic	1	0.32
UCLA Family Stress, Trauma, and Resilience Clinic	1	0.32
UCLA Muscular Dystrophy Clinic	1	0.32
UCLA Pediatric Acute-onset Neuropsychiatric Syndrome Clinic	1	0.32

Number of referrals to medical specialties, clinics, and services specific to the treatment of neurogenetic disorders. Referrals are listed in descending order by frequency within each subcategory.

Table S3 Referrals to Primary and Subspecialty Medical Care.

	N	%
Primary Care		
Internal Medicine-Pediatrics	7	2.22
Adolescent Medicine	2	0.63
Internal Medicine	1	0.32
Medical Subspecialties		
Gastroenterology	18	5.70
Cardiology/Echocardiography	15	4.75
Nephrology	6	1.90
Pulmonology/Sleep Medicine	6	1.90
Clinical Nutrition/Registered Dietician	5	1.58
Allergy and Immunology	4	1.27
Endocrinology	4	1.27
Rheumatology	2	0.63
Dermatology	1	0.32
East-West (Integrative) Medicine	1	0.32
Hematology/Oncology	1	0.32
Surgical Subspecialties		
Orthopedic Surgery and Podiatry	22	6.96
Ophthalmology	14	4.43
Otolaryngology	4	1.27
Urology	4	1.27
Gynecology	1	0.32
Neurosurgery	1	0.32
Screenings		
Audiology	8	2.53
Optometry	1	0.32
Other Specialized Medical Testing		
Renal Ultrasonography	4	1.27
Bone Age Study	1	0.32
DEXA Scan	1	0.32
Swallow Study	1	0.32

Number of referrals to primary care and to subspecialties required to manage medical comorbidities of neurogenetic disorders. Referrals are listed in descending order by frequency within each subcategory.

Table S4 Genetic Diagnoses Identified in Individual Patients

Primary Genetic Diagnoses	VUS
10p22 and 10q23 Deletion Syndrome	
14q11.2 Duplication Syndrome	
15q13.3 Microdeletion Syndrome	
15q15.2q21.1 Deletion Syndrome	
16p13.11 Microduplication Syndrome	
16p13.22p12.3 Duplication Syndrome	
16q11.2 Deletion Syndrome	
17p12 Deletion Syndrome (includes <i>PMP22</i>)	
18p Deletion Syndrome	
18q21.3 Deletion Syndrome	
19q13.12 Microdeletion + 19p13 Duplication (including <i>PRKACA</i>) Syndromes	
1p36.12-13 Duplication Syndrome	22q11.22 duplication
22q11.23 Duplication Syndrome	<i>CNGA2</i> , <i>PLXNA3</i> , and <i>MTHFR</i>
2q22.2q23.3 Deletion Syndrome	
3p21.31 Microdeletion Syndrome	
3q29 Duplication Syndrome	
6q26q27 Inverted Triplication Syndrome	
7q11.2 Deletion (including <i>AUTS2</i>) Syndrome	
7q35 Deletion Syndrome	
8p23.3p23.1 Deletion and 8p23.1p11.21 Duplication	
9p22.3 Microdeletion Syndrome and Gorlin Syndrome	
9q21.13 Deletion Syndrome (includes <i>RORB</i>)	
9q34.11 Deletion Syndrome	
Autosomal Dominant Familial Hypercholesterolemia	
Autosomal Dominant Genitopatellar Syndrome (<i>KAT6B</i>) + Autosomal Dominant 46XY Disorder of Sexual Development (<i>MAP3K1</i>)	
Autosomal Dominant Intellectual Disability (<i>FOXP1</i>)	
Autosomal Dominant Intellectual Disability (<i>PURA</i>)	
Autosomal Dominant Intellectual Disability 23	
Autosomal Recessive Deafness (<i>GJB3</i> Gene H91.8X9 Mutation)	
Bannayan-Riley-Ruvalcaba Syndrome	
Bohring-Opitz Syndrome	

Primary Genetic Diagnoses	VUS
Brachydactyly Intellectual Disability Syndrome	
<i>BRWD3</i>	<i>CHD8</i> , 3p26.3 and 10p15.315.2 duplications, X-skewing
<i>CACNA1C</i>	Xp22.31 (including <i>WWOX</i>) deletion
<i>CDKL</i>	
<i>CHD2</i>	<i>HDAC8</i>
Chromosome 1 Deletion Syndrome	
<i>CLTC</i>	1p31.1 and 5q21.3 duplications
Coffin-Lowry Syndrome	
Cornelia De Lange Syndrome	
Cowden Syndrome	
<i>DDX3X</i> variant	
<i>DEAF1</i> variant	
<i>DHX30</i> variant	
Down Syndrome	
Dravet Syndrome	
Duchenne Muscular Dystrophy	
Duplication 16p11.2 Syndrome	7q31.33 deletion
Factor V Leiden	<i>MTHFR</i>
<i>FGF3</i>	8q23.1 duplication
<i>FOXP1</i>	
Galactosemia + 4q12 deletion + 17q11.2 duplication	
<i>GATAD2B</i> deletion + <i>TBC1D7</i>	8p23.2 deletion
<i>GRIN1</i> variant	
Helsmoortel-Van Der Aa Syndrome	
Hunter Syndrome	
Hypomyelinating Leukodystrophy Type 12	
<i>KIF11</i> variant with additional variants of uncertain significance in	<i>CDCA5</i> and <i>MT-ND5</i> with 8% heteroplasmy
Klinefelter Syndrome	
Lowe Syndrome	
Monosomy 9p2	
Mosaic Supernumerary 9p13.3q13 Duplication Syndrome	
Mosaic Turner Syndrome	
Noonan Syndrome	
<i>NRAS</i> variant	
<i>NRXN1</i> Deletion Syndrome	
Opitz G/BBB Syndrome	
Partial Monosomy 2q	

Primary Genetic Diagnoses	VUS
Partial Trisomy 18q	
Phelan-McDermid Syndrome	
<i>POLR3B</i> variant with additional <i>SYNE1</i> variant and gray zone Fragile X repeats (49)	
Potocki-Lupski Syndrome	
Rett Syndrome	
Say-Barber-Biesecker-Young-Simpson Syndrome with Ehlers-Danlos Syndrome Type 1	
<i>SET5D</i> variant with additional <i>KIF1A</i> variant of uncertain significance	
Smith-Lemli-Opitz Syndrome	
Smith-Magenis Syndrome	
Snyder-Robinson Syndrome	
Stickler Syndrome	
Triple X Syndrome	
<i>TTN</i> variant with additional <i>KIF7</i> variant of uncertain clinical significance	
Ulrich Myopathy (<i>COL6A1</i>)	
Unbalanced t(8;12)	
VACTERL Association	
Xp11.23P11.22 Microduplication Syndrome	
Xp22.33p22.31 Deletion Syndrome	
<i>ZNF462</i> variant	

Table S5: Full Management Implications for Patients Diagnosed with Genetic Disorders in CARING Clinic

Genetic Finding for Patient	Management Implications
3p25	Referrals for echocardiogram, renal ultrasound, ENT consult and re-evaluation of myotonia by neuromuscular specialist. Ongoing surveillance for seizures.
TSC (clinical)	Enrolled in diagnostic clinical study to search for intronic TSC variants
<i>TTN, KIF7</i>	Patient and father (whom both carried variant) receive echocardiograms. Ophthalmology referral to assess for optic atrophy and retinal pigmentation. Referral to diagnostic clinical study.
<i>ADNP</i>	Referred for sleep study, ophthalmology, cardiology, nephrology, and for brain MRI. Enrolled in ketamine infusion trial and referred to gene therapy trial as well. Psychotropic medications selected to avoid exacerbating potential known medical complications.
<i>KDM6A</i>	Referred for echocardiogram, renal ultrasound, and gastroenterologist. Had a re-evaluation of hypotonia by clinic neurologists.
<i>MECP2, HMBS</i>	Referrals to developmental pediatrics, gastroenterology, orthopedics for scoliosis evaluation, sleep apnea evaluation, EKG to assess QTc, vEEG to help decide if anti-epileptics were necessary. Reproductive counseling provided.
<i>BRD4</i>	Referrals to developmental pediatrics for autism evaluation, referral to cardiology for echocardiogram and assessment of thrombocytopenia, referred to social work to discuss long-term care. Referred to online family group.

<i>SUMF1</i>	Referred to lysosomal storage disease clinic. Recommended echocardiogram, sleep and swallow studies, abdominal ultrasound. Referred to nutritionist at metabolic clinic, gastroenterologist and, and ophthalmology.
<i>SUMF1</i>	Referred to lysosomal storage disease clinic. Recommended echocardiogram, sleep and swallow studies, abdominal ultrasound. Referred to nutritionist at metabolic clinic, gastroenterologist and, and ophthalmology.
<i>SUMF1</i>	Referred to lysosomal storage disease clinic. Recommended echocardiogram, sleep and swallow studies, abdominal ultrasound. Referred to nutritionist at metabolic clinic, gastroenterologist and, and ophthalmology.
<i>GATAD2B</i>	Enrolled in diagnostic clinical stud, reproductive counseling, referred for autism evaluation
9q34.11	Referred for brain MRI, EEG, and further evaluation of SMA at neuromuscular clinic.
8q23.1, <i>FGF3</i>	Referred for abdominal and brain MRIs, dental clinic, social work for programs for patients who are hard of hearing. Patient referred to schannomatosis clinic at for surveillance. Recommended paternal family members and siblings undergo surveillance for early-onset cancers.
<i>FOXP1</i>	Referred to gastroenterology, neurology, developmental pediatrics, cardiology, and nephrology.
<i>CHD2, HDAC8</i>	Referred to child psychology for cognitive testing and the SIMONS VIP study and UCLA clinical research study. Increased surveillance with EEG for seizures.
<i>DHX30</i>	Referral to neuromuscular clinic, gastroenterology, orthopedics, and physical and occupational therapy. Obtained repeat brain MRI.
<i>PTEN</i>	Referred for thyroid ultrasound to monitor for cancer. Referred for behavioral therapies including ABA. Referred to neurology and dermatology for initiation of Everolimus.
Opitz G/BBB syndrome	Referred to ENT for management of laryngeal cleft. Patient ultimately received surgery that helped with breathing symptoms. Referred to gastroenterology, cardiology and ophthalmology.
2q22.3 q23.3	Referred for hand x-rays to assess for anomalies seen in potential Coffin-siris syndrome, including hypoplastic middle and distal phalanges. Recommended testing of grandparents. Able to explain that transient cardiomyopathy and recurrent ear infections and UTIs were related to genetic disorder (but did not initiate new referrals). Recommended family member get evaluated for further phenotypic characterization.
<i>SMS</i>	Referral to Undiagnosed Diseases Program, gastroenterology, nephrology, and orthopedics. Referral for neurodevelopmental evaluation and behavioral therapy, and recommended parents connect with other families on social media for community support.
<i>COL6A1</i>	Referral to neuromuscular specialist
15q11.2q13.3	Referral to clinical research studies. Encouraged to participate in dup15q family conference, connected to families with same condition, aggressive monitoring for development of seizures, which guided recommendations for anti-epileptic medication management.
8p23.3p23.1, 8p23.1p11.21	Referral to ophthalmology, developmental pediatric, cardiology, nephrology, brain MRI, orthopedic surgery, and a UCLA clinical research study.
<i>ZNF462</i>	Based on GeneMatcher findings, recommended surveillance for leukemia and make referral to endocrinology. Recommended echocardiogram, abdominal ultrasound, renal ultrasound, regional center connection and services, intensive behavioral services, feeding therapy
18q21.3	Mother tested and given reproductive counseling. Referral to urology, orthopedics, cardiology, nephrology, ophthalmology, cerebral palsy clinic, regional center and early intervention.
9p13.3q13	Provided reproductive counseling to family members. Encouraged mother to seek out community support on social media.
<i>CLTC</i> , 1p31.1, 5q21.3	Reproductive counseling. Referred to diagnostic clinical research study.
<i>SETD5, KIF1A</i>	Genetic counseling.
Xp22.33>Xp22.31	Reproductive counseling for parents. Close surveillance of seizure onset.
<i>LDLR</i>	Referred to cardiology, ataxia clinic, and clinical research study.

<i>GNAQ, PIK3CA</i>	Referral to overgrowth syndrome clinic for dental and orthopedic care.
<i>RAI1 (17p11.2), MYO15A</i>	Brain MRI, clarified that patient is not at risk of neuropathy, advised prenatal testing should be discussed with obstetrician, speech evaluation.
<i>NRAS</i>	EKG, echocardiogram, CBC, TSH, repeat cardiac exams in adolescence, monitor for symptoms of lymphatic complications and seizures.
<i>PURA</i>	Referral to cerebral palsy clinic and sleep study. Surveillance for seizures. Consideration of dopaminergic medications, and referral for intensive behavioral services for developmental delays and hypotonia.
<i>POLR3B and SYNE1</i>	Parental genetic testing. Evaluation for Tourette's that may be genetically linked. Creatine kinase level through primary care doctor.
<i>F5</i>	Shared results with family and provided education, documentation limited on further impact on management.